Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein

Atherosclerosis. 1990 Jun;82(3):185-91. doi: 10.1016/0021-9150(90)90039-l.


Oxidatively modified low density lipoprotein (LDL) could contribute to the atherosclerotic process by its cytotoxic effect, uptake by the scavenger receptor and influence on monocyte and macrophage motility. The aim of the present study was to examine the effect of physiologic levels of alpha-tocopherol and ascorbate on Cu2(+)-induced oxidative modification of LDL. Whereas alpha-tocopherol had an inhibitory effect on the oxidative modification of LDL only for 5 h, as evidenced by the electrophoretic mobility and lipid peroxide content, ascorbate inhibited the oxidative modification of LDL for both 5 and 24 h. By inhibiting the oxidative modification of LDL, ascorbate prevented the uptake and degradation of oxidatively modified LDL by the scavenger-receptor mechanism of cultured human monocyte derived macrophages. It thus appears that in this cell-free system (2.5 microM Cu2+), ascorbate is a more potent antioxidant than alpha-tocopherol. These findings indicate that ascorbate in physiologic concentrations should inhibit the oxidate modification of LDL in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ascorbic Acid / pharmacology*
  • Copper / pharmacology
  • Electrophoresis
  • Humans
  • Lipoproteins, LDL / metabolism*
  • Oxidation-Reduction
  • Vitamin E / pharmacology


  • Lipoproteins, LDL
  • Vitamin E
  • Copper
  • Ascorbic Acid